MOMA Therapeutics

With our lead asset MOMA-313, we're utilizing cutting-edge techniques in small molecule #drugdiscovery, targeting cancers like breast, prostate, pancreatic, and ovarian that have proven difficult to treat. This breakthrough drug is a small molecule inhibitor that targets DNA polymerase theta, a crucial protein in tumors with compromised DNA repair mechanisms. This is an exciting time in our journey to deliver life-changing therapies to the patients who need them most. Learn more about MOMA-313 from our Chief Scientific Officer, Peter Hammerman, below and at momatx.com.

Today, we’re pleased to share a strategic collaboration and exclusive license agreement with Bayer, to develop a small molecule #oncology candidate based on our proprietary KNOMATIC™ platform. This is an exciting moment for MOMA, further validating the power of our platform and approach to bringing powerful precision medicines to patients. Bayer will be responsible for further preclinical development and commercial activities, and we are excited to see this effort proceed after our recent news of advancing our wholly owned Pol theta and Werner programs. Discover more at https://lnkd.in/edVYe-J7

The MOMA team was honored to welcome Susan Feinberg, who is living with a #HereditaryCancer, to our summer retreat. Susan, pictured with a photo of her grandmother and cousin who both passed away from breast cancer as a result of their shared BRCA1 mutation, shared her diagnosis and treatment journey with us, helping to illuminate the real-life impact hereditary cancer can have across various cancer types and mutations. Coordinated with FORCE: Facing Our Risk of Cancer Empowered, this opportunity to hear from Susan brought us renewed perspective on our collective mission and promise of our work. This #NationalHereditaryCancerWeek, we reflect on the #1FORCECommunity of people – hereditary cancer survivors, previvors, caregivers and family members, and continue our work with heightened inspiration and motivation to keep pushing for the next generation of #geneticmedicines. For more information on Hereditary Cancer and FORCE, visit https://lnkd.in/dmY47RCZ 

We’d like to share a warm MOMA welcome to Audrey Hecht as she recently joined our biochemistry and biophysics department as a Senior Research Associate I! MOMAtes have a unique sense of courage, each bringing sharp expertise to the table and Audrey is no exception. We admire her deep curiosity and drive to produce an impactful output. Her qualities go a long way at MOMA, and we're excited to have her on our team. 

Our team comprises seasoned leadership, a highly specialized workforce with deep expertise in discovery and development an unparalleled drive to accomplish great things. We set ourselves apart with two wholly owned oncology assets, a strong pipeline of novel, high-value pre-clinical candidates, and our proprietary KNOMATIC™ Platform. Listen to MOMA CEO, Asit Parikh, M.D., Ph.D., below on our differentiation factors. 

As we begin to say goodbye to the summer months in Boston, we’re reflecting on the major accomplishments we made and special moments MOMAtes shared, from well-earned ice cream breaks to our wellness challenge. Our team’s dedication and passion have driven us forward and we’re excited to carry this momentum into the rest of the year!

As a clinical-stage company, MOMA has a significant responsibility not only to pursue the power of highly dynamic proteins that underlie human disease, but to do so rapidly and skillfully for patients in need. We’re advancing two wholly-owned, potentially best-in-class, #oncology assets enabled by our proprietary KNOMATIC Platform. Hear from the team on what this next stage means to us, and how we’re committed to adapting and evolving in rhythm with company growth. Learn more: https://lnkd.in/efssQfgT

MOMA Chief People and Experience Officer, Adam Thomas (he/him) will be at the Cambridge Healthtech Institute #CHIBioprocessingSummit today, taking part in two panels during their "Talent in Biopharma" workshop. We're excited for Adam to offer his expert perspective alongside other industry leaders on their best people practices and growth strategies. Check it out and register: https://lnkd.in/eqYsS33

Today marks a significant milestone for MOMA. We have dosed the first patient in the Phase 1 clinical trial for MOMA-313, a novel, highly potent and selective oral polymerase theta helicase inhibitor. MOMA-313 is being developed for subgroups of #prostatecancer, #pancreaticcancer and #breastcancer. To add to this exciting news, we are thrilled to share the selection of a development candidate for our second lead program, MOMA-341, an oral, potent and selective covalent Werner helicase inhibitor for the treatment of cancers with microsatellite instability. The MOMA team has worked hard to bring these two potential best-in-class molecules to the clinic through our proprietary KNOMATIC platform. Learn more about our MOMA-313, MOMA-341 and our KNOMATIC platform from MOMA CEO, Asit Parikh, M.D., Ph.D., below and read the release: https://lnkd.in/eVd3qR46

Our proprietary platform has been intentionally designed with optimized components for the sole purpose of drugging highly dynamic proteins and is built with unprecedented scale. With the power of #machinelearning and #AI, we can predict hit-finding outcomes with greater accuracy and enable a continuous learning loop that builds upon and expands our knowledge base, increasing sophistication and efficiency in our drug discovery endeavors. Learn more about our platform below and at momatx.com.